menu
    • menu
    [{"orgOrder":0,"company":"Cerveau Technologies","sponsor":"Lexeo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Licensing Agreement","leadProduct":"LX1001","moa":"Apolipoprotein E (APOE)","graph1":"Neurology","graph2":"Phase I","graph3":"Cerveau Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Infusion","sponsorNew":"Cerveau Technologies \/ Lexeo Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Cerveau Technologies \/ Lexeo Therapeutics"},{"orgOrder":0,"company":"Cerveau Technologies","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Collaboration","leadProduct":"ALN-APP","moa":"APP messenger RNA (APP mRNA)","graph1":"Neurology","graph2":"Phase I","graph3":"Cerveau Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Cerveau Technologies \/ Alnylam Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Cerveau Technologies \/ Alnylam Pharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals by Cerveau Technologies

    Menu

    Cerveau Technologies

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Cerveau Technologies

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed

                            Cerveau Technologies

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LX1001

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Lexeo Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Cerveau Technologies Inc. and LEXEO Therapeutics, Inc.- Sign Agreement to Provide Novel Tau Imaging Biomarker ...

                            Details : LX1001-01 (AAVrh.10hAPOE2) is an AAV-based investigational gene therapy candidate designed as a one-time treatment delivering a protective APOE2 gene into the CNS for the treatment of APOE4-associated Alzheimer’s disease.

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            July 11, 2022

                            Lead Product(s) : LX1001

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Lexeo Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Cerveau Technologies

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed

                            Cerveau Technologies

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ALN-APP

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Alnylam Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Cerveau Technologies Inc. and Alnylam® Pharmaceuticals Sign Agreement to Provide Novel Tau Imaging Biomarker ...

                            Details : The collaboration is focused on using [F-18]MK-6240 as a biomarker in neurodegenerative disease drug research and development. The companies will apply [F-18]MK-6240 imaging to evaluate Alnylam’s therapeutic ALN-APP, for the treatment of neurodegenerat...

                            Product Name : ALN-APP

                            Product Type : Oligonucleotide

                            Upfront Cash : Undisclosed

                            January 09, 2022

                            Lead Product(s) : ALN-APP

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Alnylam Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Cerveau Technologies

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed

                            Cerveau Technologies

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 18-F MK-6240

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Recipient : University of Wisconsin, Madison

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Longitudinal Evaluation of a Radiotracer for Use in Tau Tracking

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compounds

                            Upfront Cash : Inapplicable

                            April 18, 2019

                            Lead Product(s) : 18-F MK-6240

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Recipient : University of Wisconsin, Madison

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth